HC Wainwright Brokers Reduce Earnings Estimates for TSE:EPR

Eupraxia Pharmaceuticals Inc. (TSE:EPR) – Analysts at HC Wainwright decreased their Q4 2026 earnings per share estimates for shares of Eupraxia Pharmaceuticals in a research report issued on Wednesday, November 11th. HC Wainwright analyst B. Folkes now expects that the company will earn ($0.41) per share for the quarter, down from their previous forecast of ($0.40). HC Wainwright also issued estimates for Eupraxia Pharmaceuticals’ FY2027 earnings at ($1.89) EPS, FY2028 earnings at ($1.75) EPS, FY2029 earnings at ($1.36) EPS and FY2030 earnings at $0.20 EPS.

A number of other equities analysts also recently commented on the company. Wedbush raised Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, September 24th. Royal Bank Of Canada started coverage on shares of Eupraxia Pharmaceuticals in a report on Monday. They issued a “moderate buy” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Strong Buy”.

Eupraxia Pharmaceuticals Price Performance

Eupraxia Pharmaceuticals Inc. is a Canadian clinical-stage biotechnology company developing locally acting therapies designed to improve the delivery, duration and tolerability of established medicines. The company’s platform, DiffuSphere, uses biodegradable polymeric microspheres to provide controlled and sustained drug release at targeted sites in the body. Eupraxia’s lead programs include EP-104IAR, an extended-release intra-articular formulation intended to provide longer-lasting relief for people with knee osteoarthritis, and EP-104GI, an orally administered formulation being developed for gastrointestinal diseases, including eosinophilic esophagitis.